Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents

被引:74
作者
Drolet, B [1 ]
Simard, C [1 ]
Roden, DM [1 ]
机构
[1] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37232 USA
关键词
torsades de pointes; drugs; ion channels;
D O I
10.1161/01.CIR.0000109484.00668.CE
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background - Cases of QT prolongation, torsades de pointes, and sudden death have been reported with arsenic trioxide (As2O3), a highly effective agent for acute promyelocytic leukemia. In this study, we evaluated the effects of As2O3 on repolarizing cardiac ion currents. Methods and Results - In HERG- or KCNQ1 + KCNE1-transfected CHO cells (n = 32; total), As2O3 caused concentration-dependent block of both I-Kr and I-Ks, with an IC50 for tail current block of 0.14 +/- 0.01 mumol/L for I-Kr and 1.13 +/- 0.06 mumol/L for I-Ks. In contrast to other QT-prolonging drugs, As2O3 also activated a time-independent current that additional experiments identified as IK-ATP. Conclusions - As2O3 blocks both I-Kr and I-Ks at clinically relevant concentrations. On the other hand, it also activates IK-ATP, which maintains normal repolarization. We infer that variability in the extent of QT interval prolongation and onset of ventricular arrhythmias during arsenic therapy represents competing effects to block and activate multiple repolarizing potassium currents.
引用
收藏
页码:26 / 29
页数:4
相关论文
共 18 条
  • [1] Effect of arsenic trioxide on QT interval in patients with advanced malignancies
    Barbey, JT
    Pezzullo, JC
    Soignet, SL
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (19) : 3609 - 3615
  • [2] Prolongation of cardiac repolarization by arsenic trioxide
    Chiang, CE
    Luk, HN
    Wang, TM
    Ding, PYA
    [J]. BLOOD, 2002, 100 (06) : 2249 - 2252
  • [3] USE-DEPENDENT EFFECTS OF THE CLASS-III ANTIARRHYTHMIC AGENT NE-10064 (AZIMILIDE) ON CARDIAC REPOLARIZATION - BLOCK OF DELAYED RECTIFIER POTASSIUM AND L-TYPE CALCIUM CURRENTS
    FERMINI, B
    JURKIEWICZ, NK
    JOW, B
    GUINOSSO, PJ
    BASKIN, EP
    LYNCH, JJ
    SALATA, JJ
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1995, 26 (02) : 259 - 271
  • [4] Fiset C, 1997, J PHARMACOL EXP THER, V283, P148
  • [5] Assembly limits the pharmacological complexity of ATP-sensitive potassium channels
    Giblin, JP
    Cui, Y
    Clapp, LH
    Tinker, A
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (16) : 13717 - 13723
  • [6] KLAASSEN CD, 2001, GOODMAN GILMANS PHAR, P1851
  • [7] Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia
    Ohnishi, K
    Yoshida, H
    Shigeno, K
    Nakamura, S
    Fujisawa, S
    Naito, K
    Shinjo, K
    Fujita, Y
    Matsui, H
    Takeshita, A
    Sugiyama, S
    Satoh, H
    Terada, H
    Ohno, R
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 133 (11) : 881 - 885
  • [8] Exploring the hidden danger of noncardiac drugs
    Priori, SG
    [J]. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 1998, 9 (10) : 1114 - 1116
  • [9] Risk/benefit profile of arsenic trioxide
    Rust, DM
    Soignet, SL
    [J]. ONCOLOGIST, 2001, 6 : 29 - 32
  • [10] Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APE) .2. Clinical efficacy and pharmacokinetics in relapsed patients
    Shen, ZX
    Chen, GQ
    Ni, JH
    Li, XS
    Xiong, SM
    Qiu, QY
    Zhu, J
    Tang, W
    Sun, GL
    Yang, KQ
    Chen, Y
    Zhou, L
    Fang, ZW
    Wang, YT
    Ma, J
    Zhang, P
    Zhang, TD
    Chen, SJ
    Chen, Z
    Wang, ZY
    [J]. BLOOD, 1997, 89 (09) : 3354 - 3360